Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1c Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine (MV-012-968) in Seronegative Children 6-36 Months
Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Phase 1c Study to Evaluate the Safety and Immunogenicity of an Intranasal Live Attenuated Respiratory Syncytial Virus Vaccine (MV-012-968) in Seronegative Children 6-36 Months
This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically, the study analyzes the safety of, and the immune response to, the vaccine when administered to healthy children between the ages of 6 and 24 months who are seronegative to RSV.
Key Inclusion Criteria:
Key Exclusion Criteria:
jay.lieberman@meissavaccines.com3107538943
Phoenix, Arizona 85015, United States
JasonWallace@medpharmics.co602-368-1928
jhowlett@paradigm-research.com858-274-4226
avanducen@paradigm-research.com858-274-4226
lisa.simmons.macoy@emory.edu404-727-8440
mireya@crprime.com208-497-0600 ext. 124
karley@crprime.com208-497-0600
katelynvinet@medpharmics.com504-304-7197
mstahr@mcrmed.com402-407-2800
krjohnson@mcrmed.com402-407-2800
ANichols@mcrmed.com402-933-6500
KOlmstead@mcrmed.com607-771-1064 ext. 41348
cwilson@aventivresearch.com614-501-6164 ext. 2022
sgaines@aventivresearch.co614-501-6164 ext. 3009
mthomas@cpakids.com843-518-5646
emccoy@cpakids.com843-737-9471
lmagana@panamclinicalresearch.com956-443-0016
pgarza@panamclinicalresearch.com956-443-0016
jaudohnhicks@benchmarkresearch.net210-697-3600 ext. 6
aprilvaldvieso@benchmarkresearch.net210-697-3600 ext. 6